Navegar por autor "García Campelo, María del Rosario"

10(th) Congress on Lung Cancer-updates on clinical trials: goal

2014- García Campelo, María del Rosario

A phase II, multicenter, four-cohort study of oral cMET inhibitor capmatinib (INC280) in patients with EGFR wild-type, advanced NSCLC who have received one or two prior lines of systemic therapy for advanced/metastatic disease

2015- García Campelo, María del Rosario

Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry

2014- Abdulkader Nallib, Ihab; García Campelo, María del Rosario

Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program

2022- Bernabé-Caro, R.; Garrido, P.; García Campelo, María del Rosario; Palmero, R.; Artal, Á.; [et al.]

Assessment of the psychosocial and economic impact according to sex in non-small cell lung cancer patients: an exploratory longitudinal study

2020- Viñolas, N Nuria; García Campelo, María del Rosario; Majem, Margarita; Carcereny, Enric; Isla, Dolores; [et al.]

Astrocyte elevated gene 1 (AEG-1) mRNA expression in non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations

2011- García Campelo, María del Rosario

BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer

2015- García Campelo, María del Rosario

BIM and SHP2 expression levels to predict clinical outcome to EGFR tyrosine kinase inhibitors (TKI) in EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p)

2015- García Campelo, María del Rosario; Alonso-Jaudenes Curbera, Guillermo

Brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial

2019- Califano, R; Hochmair, M J; Gridelli, C; Delmonte, A; García Campelo, María del Rosario; [et al.]

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

2020- Camidge, D Ross; Kim, Hye Ryun; Ahn, Myung-Ju; Yang, James C H; Han, Ji-Youn; [et al.]

Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping

2019- Zugazagoitia, J; Ramos, I; Trigo, J M; Palka, M; Gomez-Rueda, A; [et al.]

Cost-Effectiveness of Next-Generation Sequencing Versus Single-Gene Testing for the Molecular Diagnosis of Patients With Metastatic Non-Small-Cell Lung Cancer From the Perspective of Spanish Reference Centers

2023- Arriola, E.; Bernabé, R.; García Campelo, María del Rosario; Biscuola, M.; Enguita, A.B.; [et al.]

Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics

2022- Provencio, M.; Cobo, M.; Rodriguez-Abreu, D.; Calvo, V.; Carcereny, E.; [et al.]

DUART: durvalumab after radiotherapy in patients with unresectable, stage III NSCLC who are ineligible for chemotherapy

2021- Filippi, Andrea R; Dziadziuszko, Rafał; García Campelo, María del Rosario; Paoli, Jean-Baptiste; Sawyer, William; [et al.]

Effect of central nervous system (CNS) metastases in a real-world multicenter cohort study of Spanish ALK-positive non-small cell lung cancer (NSCLC) patients (p)

2019- Angelats L; García Campelo, María del Rosario; Bernabe Caro R; Arriola Aperribay E; Calvo de Juan V; [et al.]

Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations

2023- Bearz, A.; Martini, J.-F.; Jassem, J.; Kim, S.-W.; Chang, G.-C.; [et al.]

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial

2012- García Campelo, María del Rosario

Evaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapy

2019- RUIZ BAÑOBRE, JUAN; Areses Manrique, María Carmen; Mosquera-Martinez, J.; Cortegoso Mosquera, Alexandra Sabela; Afonso-Afonso, F. J.; [et al.]

Expression of notch1 to -4 and their ligands in renal cell carcinoma: A tissue microarray study

2011- Antón Aparicio, Luis Miguel; Aparicio Gallego, Guadalupe; Medina Villaamil, Vanessa; Santamarina Cainzos, Isabel; Fernández Calvo, Ovidio; [et al.]

Fructose transporter GLUT5 expression in clear renal cell carcinoma

2011- Valladares Ayerbes, Manuel; Antón Aparicio, Luis Miguel; Aparicio Gallego, Guadalupe; Medina Villaamil, Vanessa; Santamarina Cainzos, Isabel; [et al.]

Repositorio digital RUNA

Navegar por autor "García Campelo, María del Rosario"

10(th) Congress on Lung Cancer-updates on clinical trials: goal ﻿

A phase II, multicenter, four-cohort study of oral cMET inhibitor capmatinib (INC280) in patients with EGFR wild-type, advanced NSCLC who have received one or two prior lines of systemic therapy for advanced/metastatic disease ﻿

Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry ﻿

Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program ﻿

Assessment of the psychosocial and economic impact according to sex in non-small cell lung cancer patients: an exploratory longitudinal study ﻿

Astrocyte elevated gene 1 (AEG-1) mRNA expression in non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations ﻿

BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer ﻿

BIM and SHP2 expression levels to predict clinical outcome to EGFR tyrosine kinase inhibitors (TKI) in EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p) ﻿

Brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial ﻿

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial ﻿

Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping ﻿

Cost-Effectiveness of Next-Generation Sequencing Versus Single-Gene Testing for the Molecular Diagnosis of Patients With Metastatic Non-Small-Cell Lung Cancer From the Perspective of Spanish Reference Centers ﻿

Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics ﻿

DUART: durvalumab after radiotherapy in patients with unresectable, stage III NSCLC who are ineligible for chemotherapy ﻿

Effect of central nervous system (CNS) metastases in a real-world multicenter cohort study of Spanish ALK-positive non-small cell lung cancer (NSCLC) patients (p) ﻿

Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations ﻿

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial ﻿

Evaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapy ﻿

Expression of notch1 to -4 and their ligands in renal cell carcinoma: A tissue microarray study ﻿

Fructose transporter GLUT5 expression in clear renal cell carcinoma ﻿

10(th) Congress on Lung Cancer-updates on clinical trials: goal

A phase II, multicenter, four-cohort study of oral cMET inhibitor capmatinib (INC280) in patients with EGFR wild-type, advanced NSCLC who have received one or two prior lines of systemic therapy for advanced/metastatic disease

Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry

Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program

Assessment of the psychosocial and economic impact according to sex in non-small cell lung cancer patients: an exploratory longitudinal study

Astrocyte elevated gene 1 (AEG-1) mRNA expression in non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations

BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer

BIM and SHP2 expression levels to predict clinical outcome to EGFR tyrosine kinase inhibitors (TKI) in EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p)

Brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping

Cost-Effectiveness of Next-Generation Sequencing Versus Single-Gene Testing for the Molecular Diagnosis of Patients With Metastatic Non-Small-Cell Lung Cancer From the Perspective of Spanish Reference Centers

Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics

DUART: durvalumab after radiotherapy in patients with unresectable, stage III NSCLC who are ineligible for chemotherapy

Effect of central nervous system (CNS) metastases in a real-world multicenter cohort study of Spanish ALK-positive non-small cell lung cancer (NSCLC) patients (p)

Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial

Evaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapy

Expression of notch1 to -4 and their ligands in renal cell carcinoma: A tissue microarray study

Fructose transporter GLUT5 expression in clear renal cell carcinoma